Donald Trump's order on psychedelic drugs sent shares of companies in the space surging. RFK Jr and Joe Rogan were present at ...
BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...
Asahi Kasei broadened its infectious disease franchise via Aicuris, adding commercial and clinical-stage antivirals aimed at ...
13h
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing ...
Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition ...
Physician-scientist and drug discovery leader to guide next phase of translational medicine program ...
Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results